Nucleostemin depletion induces
post-G1 arrest apoptosis in chronic myelogenous leukemia K562 cells by Negin Gogani et al.
 
 
Advanced Pharmaceutical Bulletin, 2014, 4(1), 55-60 
doi: http://dx.doi.org/10.5681/apb.2014.009 
http://apb.tbzmed.ac.ir/ 
 
*Corresponding author: Mohammad Amin Moosavi, Nanobiomaterial and Tissue Engineering Research Center, National Institute of Genetic 
Engineering and Biotechnology, P.O Box: 14965/161, Tehran, Iran. Tel.: +98 21 44580335, Fax: +98 21 44580399, Email: a-moosavi@nigeb.ac.ir 
Copyright © 2014 by Tabriz University of Medical Sciences 
Nucleostemin Depletion Induces Post-G1 Arrest Apoptosis in Chronic 
Myelogenous Leukemia K562 Cells 
Negin  Seyed-Gogani
1,  Marveh  Rahmati
2,  Nosratollah  Zarghami
2,3,  Iraj  Asvadi-Kermani
3,  Mohammad  Ali 
Hoseinpour-Feyzi
1, Mohammad Amin Moosavi
1,3,4* 
1 Department of Zoology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran. 
2 Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran. 
3 Hematology and Oncology Research Center, Tabriz University of Medical Science, Tabriz, Iran. 
4 National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Chronic  myelogenous  leukemia  (CML)  is  a  clonal 
pluripotent  hematopoietic  stem  cell  disorder  caused  by 
indefinite  proliferation  of  leukemic  stem  cells  (LSCs).
1 
Reciprocal  translocation  between  the  abl  gene  (on 
chromosome  9)  and  the  bcr  gene  (on  chromosome  22) 
causes  formation  of  Bcr-Abl  oncogene.
1,2  The  fusion 
product of Bcr-Abl is an oncogenic protein displays up-
regulated  tyrosine  kinase  activity.
2  At  present,  CML 
therapies  mostly  included  chemotherapy,  differentiation 
therapy,  α-interferon  treatment,  Bcr-Abl  tyrosine  kinase 
inhibitors  and  bone  marrow  transplantation.
3,4  Although, 
recent  tyrosine  kinase  inhibitors  improved  therapeutical 
options  in  CML  patients,  some  adverse  effects  such  as 
drug resistance and late relapse were observe in clinical 
trials.
5  It  has  been  suggested  that  current  therapeutic 
approaches  would  not  completely  eliminate  all  LSC  in 
CML patients and relapse of disease was observed. In fact, 
unlimited  self-renewal  capacity  and  impaired 
differentiation  property  of  LSCs  allow  continuously 
proliferation  and  prevent  terminal  differentiation  and 
apoptosis that normally occur in blood cells.
6,7 Obviously, 
elucidation  of  the  mechanisms  involved  in  LSC 
proliferation,  differentiation  and  apoptosis  enumerates 
first-line  investigations  for  improving  CML  therapeutic 
strategies. 
In 2002, Tsai and McKay discovered that a novel gene 
called  Nucleostemin  (NS),  apparently  expressed  in  rat 
embryonic and adult central nervous system stem cells.
8 
The protein coded by NS gene was found in the nucleoli of 
undifferentiated cells, such as adult and embryonic stem 
cells, neural stem cells and human bone marrow stem cells 
but not in differentiated counterpart cells, indicating that 
NS  is  silenced  during  normal  cells  differentiation.
9,10 
Interestingly, recent reports suggest that NS gene is also 
abundantly expressed in several human cancer cell lines 
such  as  SGC-7901  (gastric),  Hela  (cervical),  5637 
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Purpose:  Despite  significant  improvements  in  treatment  of  chronic  myelogenous 
leukemia  (CML),  the  emergence  of  leukemic  stem  cell  (LSC)  concept  questioned 
efficacy of current therapeutical protocols. Remaining issue on CML includes finding 
and targeting of the key genes responsible for self-renewal and proliferation of LSCs. 
Nucleostemin (NS) is a new protein localized in the nucleolus of most stem cells and 
tumor cells which regulates their self-renewal and cell cycle progression. The aim of this 
study was to investigate effects of NS knocking down in K562 cell line as an in vitro 
model of CML.  
Methods: NS gene silencing was performed using a specific small interfering RNA (NS-
siRNA). The gene expression level of NS was evaluated by RT-PCR. The viability and 
growth rate of K562 cells were determined by trypan blue exclusion test. Cell cycle 
distribution of the cells was analyzed by flow cytometry. 
Results: Our results showed that NS knocking down inhibited proliferation and viability 
of K562 cells in a time-dependent manner. Cell cycle studies revealed that NS depletion 
resulted  in  G1 cell  cycle  arrest  at  short  times  of  transfection  (24  h)  followed  with 
apoptosis at longer times (48 and 72 h), suggest that post-G1 arrest apoptosis is occurred 
in K562 cells.  
Conclusion: Overall, these results point to essential role of NS in K562 cells, thus, this 
gene might be considered as a promising target for treatment of CML. 
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(bladder), PC-3 (prostate), and HL-60 (acute myelocytic 
leukemia).
11-15 In parallel with significant of this gene in 
cancer,  several  knocking  down  experiments  using  RNA 
interference  (RNAi)  showed  that  inhibition  of  NS  gene 
expression markedly inhibited proliferation and cell cycle 
progression of cancerous cells followed with induction of 
differentiation  and/or  apoptosis.
11-15  Recently,  a  high 
expression  level  of  NS  has  been  reported  in  leukemia 
patients, particularly CML.
15 Consistent with this, RNAi-
mediated  NS  knocking  down  inhibited  proliferation  and 
induced  differentiation  and  apoptosis  in  HL-60  human 
acute  myeloblastic  leukemia.
16  However,  importance  of 
NS in other types of leukemia, especially CML, needs to 
be addressed.  
This  study  was  designed  to  investigate  functional 
importance  and  therapeutic  potential  of  NS  gene 
expression and effects of NS knockdown on cell cycle and 
apoptosis  in  K562  cells.  Our  result  showed  that  RNA 
interference  (RNAi)-mediated  NS  silencing  induced  G1 
cell  cycle  arrest  followed  with  apoptosis  in  K562 
leukemia cells. 
 
Materials and Methods 
Cell culture 
The human K562 cell line was cultured in RPMI 1640 
medium supplemented with  heat-inactivated fetal  bovine 
serum (10% v/v), streptomycin (100μg/ml) and penicillin 
(100 U/ml) at 37 °C in a humidified atmosphere of 5% 
CO2.  
 
siRNA design and synthesis 
NS specific double-stranded small interfering RNA (NS-
siRNA) was designed by siRNA target finder program at 
the  Ambion  website: 
(http://www.ambion.com/techlib/misc/ 
siRNA_finder.html).  The  NS-siRNA  and  irrelevant 
scrambeled  siRNA  (IR-siRNA)  oligonucleotides  were 
synthesized  by  Eurofin  MWG  Operon  (Germany).  A 
siRNA labeled by fluorescein at 3' end of antisense strand 
was used to determine efficiency of cellular transfection. 
The sense and antisense sequence of NS-siRNA and IR-
siRNA were as followed: 
 NS-siRNA  Sense:  5'-
GAACUAAAACAGCAGCAGAdTdT-3'  and  Antisense: 
5'-UCUGCUGCUGUUUUAGUUCdTdT-3' 
IR-siRNA (Sense: 5'-CACCGCCTCTCATCGTCGTC-3', 
Antisense: AAUCAGACGUGGACCAGAAGAdTdT) 
 
K562 cells transfection 
The day before transfection, cells were diluted at a density 
of 3 × 10
5/ml in culture medium containing FBS (10%) 
and antibiotics in cell culture flask. After 24 h, 2 × 10
5 
cells/  well  were  seeded  in  24-well  plates  (SpL  Life 
sciences,  South  Korea)  with  100  μl  culture  medium 
containing  FBS  (10%)  and  antibiotics.  For  cell 
transfection,  200  nM  siRNA  associated  with  6  μl 
HiPerfect (Qiagen, USA) transfection reagent and 100 μl 
serum free medium mixed and vortexed. This mixture was 
incubated for 10 min at room temperature and then added 
to cells. After 6 h, 400 μl culture medium containing FBS 
(12.5%) and antibiotics were added to the cells. 
 
RNA  extraction  and  reverse  transcriptase  polymerase 
chain reaction (RT-PCR) 
Total RNA was isolated from transfected cells as well as 
untransfected cells 12-72 h after transfection, using RNX 
plus™ (Cinagen, Tehran) according to the manufacturer’s 
protocol. Total RNA (1 g) converted to cDNA in a final 
volume of 20 l by oligo dT and RevertAid™ M-MuLV 
reverse  transcriptase  (Fermentase,  UK).  PCR  reactions 
were  carried  out  using  Taq  DNA  polymerase.  The 
sequences of primers for all isoforms of NS (NM014366, 
NM206825,  NM206826)  were:  Reverse:  5  '-
AAAGCCATTCGGGTTGGAGT-3',  Forward:  5'-
ACCACAGCAGTTTGGCAGCAC-3'.  β2microglobulin 
(β2m) gene was used as a control for adjusting the relative 
amounts of total RNA between the samples. β2m forward 
primer and reverse primer were 5'- CTA CTC TCT CTT 
TCT GGC CTG-3' and 5'- GAC AAG TCT GAA TGC 
TCC AC-3', respectively. PCR for NS gene included an 
initial denaturation step at 94 °C for 2 min, followed by 35 
amplification cycles  consisting  of  denaturation  at  94  °C 
for 30 s, annealing at 60 ˚C for 40 s, extension at 72 °C for 
1 min and final extension at 72 °C for 5 min (418 bp). 
PCR for β2m gene included an initial denaturation step at 
94  °C  for  5  min,  followed  by  30  amplification  cycles 
consisting of denaturation at 94 °C for 30 s, annealing at 
57 ˚C for 30 s, extension at 72 °C for 1 min and final 
extension  at  72  °C  for  5  min  (191  bp).  The  amplified 
product was identified by electrophoresis on 1.5% agarose 
gel.  NS  and  β2m  primers  were  synthesized  by  Eurofin 
MWG Operon (Germany). 
 
Growth inhibition and viability 
To  study  proliferation  and  viability,  the  transfected  and 
untransfected cells were seeded at a density of 2 × 10⁴ 
cells/well  in  24-well  plates.  After  different  times  of 
transfection, viable and dead cells were counted by trypan 
blue exclusion assay and percent of growth inhibition and 
cytotoxixicty were determined as mentioned previously.
17 
The transfected cells were stained with 0.4% trypan blue 
at  a  dilution  of  1:1,  and  counted  using  a  neubauer 
hemocytometer slide under an inverted light microscopy 
(Olympus,  Japan).  Morphological  studies  of  cells  were 
also  performed  by  inverted  light  microscopy  (Olympus, 
Japan). 
 
Cell cycle analyses 
DNA  contents  of  cells  were  analyzed  using  flow 
cytometry  as  described  previously.
18  Control  and 
transfected  cells  were  harvested  and  washed  twice  with 
PBS (Phosphate Buffer Saline), fixed in 70% ethanol and 
kept at −20 °C until analysis. Then the cells were stained 
with 20 μg/ml PI containing 20 μg/ml RNase (DNase free) 
for 2 h. The stained cells were analyzed by flow cytometry 
(Partec Pas, Germany). The population of G0/G1, S, G2/M 
and  sub-G1  cells  was  determined  using  Mulicycle  Cell  
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Cycle Software. The results are expressed as percentage of 
the cells in each phase. 
 
Fluorescent microscopic study of apoptosis 
Control and  transfected cells  were  washed in  cold  PBS 
and adjusted to a cell density of 5 × 10⁴ cell/20l of PBS 
and gently  mixed  with a  mixture  of AO  (1  μg/ml)  and 
EtBr (1 μg/ml) solution (1 : 1, v/v). The suspension was 
placed  on  a  microscopic  slide  and  viewed  under  a 
fluorescent microscopy (Nikon E-1000, Japan). 
 
Statistical analyses 
All data represent the mean ±SEM of three independent 
experiments. Significant differences between groups were 
evaluated  by  multiple  mean  comparisons  via  one-way 
ANOVA  test,  SPSS  14.0  and  Microsoft  Excel  210. 
P<0.05 were considered statistically significant. 
 
Results 
Expression of NS was efficiently inhibited by NS-siRNA 
in K562 cells 
Based on our preliminary data about high expression level 
of NS in leukemia cell lines, we examined different RNAi 
techniques for silencing of this gene in K562 cells.
19 One 
of  the  designed  siRNAs,  called  NS-siRNA,  could 
efficiently inhibit NS expression in K562 cells (Figure 1). 
As  depicted  in  Figure  1,  NS-siRNA  at  200  nM  was 
efficiently  delivered  into  K562  cells  (Figure  1A)  and 
significantly inhibited NS expression in a time-dependent 
manner (Figure 1B). In fact, no significant reduction in NS 
expression  was  observed  after  6-12  h  NS-siRNA 
transfection of K562 cells, whereas NS mRNA level were 
significantly  inhibited  between  16  h  and  48  h  of 
transfection (Figure 1B and C). The inhibition rate of NS 
expression in comparison with corresponding β2m internal 
control after 16 h, 24 h and 48 h were about 20%, 24% 
and 55%, respectively (Figure 1C). 
 
Figure 1. Knockdown of NS expression by siRNA in K562 cell line. 
(A) NS-siRNA delivery into  K562 cells. After 24  h of transfection  with 
fluorescein-labeled NS-siRNA, K562 cells were harvested and analyzed 
by fluorescent  microscopy.  (B) RT-PCR  study  of NS  gene  expression 
level  in  K562  cells.  Following  transfection  with  200  nM  IR-  and  NS-
siRNAs,  K562  cells  were  collected  and  mRNA  levels  of  NS  were 
dtermined  by  semi  quantitative  RT-PCR.  (C)  Analyzing  of  NS  mRNA 
level in K562 cells. The densitometry analysis of NS mRNA over β2m 
mRNA data was studied by UVItec software. Each value represents the 
mean±SEM  of  three  independent  experiments  and  P<0.05  (*)  were 
considered statistically significant. 
Knockdown  of  NS  inhibits  growth  and  viability  of 
K562 cells 
To evaluate biological consequence of  NS silencing, 
the  growth  rate  and  viability  of  K562  cells  were 
studied  for  various  time  intervals  (Figure  2).  No 
significant growth inhibitory effects were observed 12 
h  after  transfection,  while  growth  was  inhibited  by 
28.8%, 33.7% and 36.4% after 24 h, 48 h and 72 h, 
respectively (Figure 2A). In comparison with control 
or  IR-siRNA  transfected  cells,  the  viability  of  NS 
depleted  cells  was  also  reduced  but  with  different 
kinetics (Figure 2B). Indeed, no significant cell death 
was  observed  after  12-24  h  of  NS  depletion,  while 
viability of K562 cells was significantly reduced by 
17.6%  and  34.9%  after  48  h  and  72h,  respectively. 
These  findings  together  with  the  growth  results 
(Figure2A)  suggest  that  growth  inhibition  is 
prominent effects of NS-siRNA at short times while 
cell death is appeared at long times (48-72 h). 
 
 
Figure 2. Effects of NS-siRNA on growth and viability of 
K562 cells. Following transfection with 200 nM IR- and NS-
siRNAs, K562 cells were collected and number of viable cells 
(white  cells),  and  dead  cells  (blue  cells)  were  estimated  . 
Growth inhibition (a) and viability (b) were studied using trypan 
blue test , respectively. Each value represents the mean±SEM 
of three independent experiments. P<0.05 (*) were considered 
statistically significant. 
 
Knockdown of NS leads to profound morphological 
changes in K562 cells  
The  morphology  of  K562  cells  after  NS-siRNA 
transfection  was  shown  in  Figure  3.  Aggregation  of 
K562 cells and decrees in cell confluency was typically 
observed in  NS depleted  K562 cells.  However,  some 
cell death criteria such as cell shrinking and cell debris 
were observed after 48-72 h of NS-siRNA transfection. 
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Figure 3. Morphological changes of K562 leukemia cells 
after transfection with NS- siRNA. The cells were transfected 
by  200  nM  NS-siRNA  for  24-72  h,  and  then  morphological 
changes  were  studied  using  light  microscopy  (magnification 
40x). After 24 h, cell aggregation (white arrow) were observed 
in NS-siRNA transfected K562 cells whereas after longer times 
(48-72  h)  cell  shrinking  (long  black  arrows)  and  apoptotic 
bodies (short black arrows) were clearly observed. 
 
Knockdown of NS induces apoptosis in K562 cells 
To  determine  mode  of  cell  death  in  NS-siRNA 
transfection cells, we studied apoptosis and necrosis by 
AO/EtBr double staining of the cells (Figure 4). The 
results clearly showed that NS siRNA transfected cells 
underwent apoptosis after 48 h. The apoptotic criteria, 
including  nuclear  fragmentation  chromatin 
condensation,  and  apoptotic  bodies  were  clearly 
observed.  In  these  figure,  viable  cells  were  equally 
green  whereas  early  apoptotic  cells  had  bright  green 
blots in their nuclei indicating chromatin condensation 
and  nuclear  fragmentation.  Late  apoptotic  cells, 
however,  stained  orange  and  showed  condense  and 
fragmented nuclei. Necrotic cells were uniformly orange. 
 
 
Figure  4.  Apoptotic  effects  of  NS-siRNA  in  K562  cells. 
Frothy eight hours after transfection of K562 cells with 200 nM 
IR- and NS-siRNAs, the cells were collected. 
Control (IR-siRNA) and NS-siRNA transfected K562 cells were 
double  stained  with  AO/EtBr  and  studied  by  fluorescent 
microscopy (magnification, 40x).Viable cells are equally green, 
early apoptotic cells are green and contained bright green dots 
in their nuclei (short arrows) and late apoptotic cells are orange 
(long arrows). 
 
Knockdown of NS induces G0/G1 cell cycle arrest in 
K562 cells 
Evidence suggests that the cell fate decision is  made 
within G1 phase of cell cycle. Therefore, the cell cycle 
distribution of NS-siRNA transfected K562 cells was 
also studied in this work (Figure 5). When compared 
with control cells, NS-siRNA transfected cells showed 
a  significant  increase  in  G0/G1  phase  of  cell  cycle 
population  with  concurrent  decrease  in  S  and  G2M 
phase after 24 h of transfection. As might be expect, a 
sub-G1 peak (apoptotic cells) was apparent after longer 
times  of  transfection.  For  example,  After  24  h,  the 
G0/G1 cell cycle population of NS-siRNA  transfected 
cells  (59%)  was  higher  than  control  cells  (45%). 
Moreover, the sub- G1cell population (apoptotic cells) 
was  increased  from  from  18-36%  48  -72  h  of 
transfection, respectively. 
 
Discussion  
Several reports have suggested that NS is a marker of stem 
cells that is involved in controlling self-renewal, cell cycle 
progression  and  proliferation  in  both  stem  cells  and 
cancerous  cells.
10,20  As  we  took  this  matter  into 
consideration  that  NS  plays  a  critical  role  in  cell 
proliferation,  consequently,  we  examined  NS  expression 
and its function in K562 cell line as a model of CML stem 
cells. K562 cell line has been established from the pleural 
extravasation of a patient with CML in blast crisis which 
behaves  as  pluripotent  hematopoietic  stem  cells.  In 
addition to abnormal Bcr-Abl gene, K562 cells have also 
mutated p53 gene.
16 These combined mutations make the 
cells  a  suitable  and  worldwide  in  vitro  model  to  study 
effects of new chemotherapy drugs and CML stem cells 
targeted  therapies.
16  With  our  knowledge,  functional 
importance of NS in CML has not been studied until now. 
Our results indicated that NS mRNA was highly expressed 
in  K562  cells.  This  finding  is  aligned  with  previous 
studies  based  on  NS  over-expression  in  several  human 
cancer cell lines.
11-15 In our study, role of NS in cell cycle 
progress and apoptosis of K562 cells was determined by a 
NS  specific  siRNA  as  a  genomic  nanoparticle.  These 
oligos  led  to  a  significant  decrease  in  the  NS  mRNA 
expression  (Figure  1).  The  results  showed  that  NS 
knocking down inhibited growth of K562 cells 24 h after 
transfection. Apoptosis began after 48 h and increased to 
its  highest  level  after  72  h.  Therefore,  NS  depletion  in 
K562 cells resulted in growth inhibition at short times and 
apoptosis  at  longer  times.  These  results  are  in  full 
agreement with cell cycle results where an accumulation 
in G1 phase population was observed after 24 h of NS-
siRNA  transfection.  After  this  time  point,  however,  the 
cells population at G1 phase decreased and a sub-G1 peak 
was  appeared,  suggest  that  post-G1  arrest  apoptosis  is 
exact mode of action of NS-siRNA in K562 cells. Most 
literature  reports  suggest  that  NS  depletion  inhibited 
proliferation and induced cell cycle arrest in cancer cell 
lines.
13,14,21,22 For instance, NS specific siRNA in bladder 
cancer cells led to G1 cell cycle arrest in prostate  PC-3 
cells and bladder cancer 5637cells.
13,14 However, NS may 
also induce G2/M cell cycle arrest as the case of bladder 
cancer  SW1710  cells.
13  Apparently,  the  role  of  NS  in 
regulation of G1 phase of cell cycle in K562 cells are in 
full agreement with most of these literature reports.   
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Figure 5. Effects of NS-siRNA on cell cycle distribution of 
K562 cells. Following NS –siRNA transfection, the K562 cells 
were collected at different time  intervals (24-72 h) and  their 
DNA contents were analyzed by flow cytometry as mentioned 
in  materials  and  methods.  The  results  are  from  a  typical 
experiment. 
 
Although, several reports point to apoptotic effects of 
NS depletion in different cancerous cells, induction of 
apoptosis  following  G1  cell  cycle  arrest  is  a  novel 
finding  of  this  paper.  In  fact,  it  has  been  previously 
reported  that  NS  depletion  induced  a  rapid  apoptosis 
response  in  HeLa  cells,  PC-3  cells,  human  bladder 
(5637) cells and HL-60 cells.
12-14,16 In our experiments, 
however, we observed a delayed apoptosis response in 
K562 cells. This may be related to different levels of 
NS depletion and protein contents of the cells used in 
distinct experiments. 
Several  studies  have  provided  evidence  that  the  p53 
signaling  pathway  is  involved  in  cell-cycle  arrest 
induced by the NS depletion. The knockdown of NS 
enhanced  the  interaction  between  the  p53-binding 
protein MDM2 and the ribosomal protein L5 or L11, 
preventing MDM2 from inducing ubiquitylation-based 
p53  degradation.
8,21  However,  NS  depletion  induced 
cell-cycle arrest and decreased cell proliferation in rat 
bone marrow stromal stem cells and several cancerous 
cells in a p53-independent manner.
22 Considering this 
fact that K562 cells and three other cancerous cell lines 
HL-60,  PC-3  and  5637  cells  have  no  functional  p53 
protein,  it  can  be  concluded  other  proteins  might  be 
involved in NS effects.
14 It is possible that NS induces 
apoptosis via interaction with other molecules than p53. 
Consistent  with  this  conclusion,  it  has  been  reported 
that  NS  depletion  inhibited  ribosome  biogenesis  in  a 
p53-depndent manner.
23 Further works are in progress 
to address this question. 
 
Conclusion 
Attain to potent growth inhibitory and apoptotic effects 
of NS-siRNA in human myeloid leukemia K562 cells, 
the  silencing  of  this  gene  can  be  a  considered  as  a 
therapiutic target for treatment of leukemia. 
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